Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Anxiety Disorders And Depression Treatment Market Overview (2023 to 2033)

The global Anxiety Disorders and Depression Treatment Market was valued at around US$ 11.2 billion in 2021. With a projected CAGR of 3.4% for the next ten years, the market is likely to reach a valuation of nearly US$ 16.1 billion by the end of 2032. In the upcoming years, market growth is anticipated to be accelerated by efforts made jointly by pharmaceutical firms, NGOs, mental health groups, and government initiatives to raise public awareness.

Report Attributes Details
Anxiety Disorders And Depression Treatment Market Size (2021A) US$ 11.2 billion
Estimated Market Value (2022E) US$ 11.5 billion
Forecasted Market Value (2032F) US$ 16.1 billion
Global Market Growth Rate (2022 to 2032) 3.4% CAGR
United States Growth Rate (2022 to 2032) 3.2% CAGR
Key Companies Covered
  • Pfizer Inc.
  • H. Lundbeck A/S
  • Glaxo SmithKline pharmaceuticals ltd.
  • Merc Co Inc.
  • Eli Lilly & Company

Future Market Insights’ analysis reveals that in 2022 revenue through the Anxiety Disorders and Depression Treatment Market is estimated at US$ 11.5 billion. Worldwide, due to the enormous financial and emotional strain on people, families, and society as a whole, mental health illnesses are becoming more prevalent among adults. The WHO estimates that the cost of mental health issues in affluent nations ranges from 3% to 4% of GDP. As a result, the government's goal of lessening the financial burden of these disorders is likely to spur product demand and ensure prompt management of anxiety and depression.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Anxiety Disorders and Depression Treatment Market from 2015 to 2021 Vs Market Outlook for 2022 to 2032

The global market for Anxiety Disorders and Depression Treatment Market expanded at a CAGR of 2.7% from 2015 to 2021. Around 284 million people worldwide suffer from anxiety, yet only 36% of them seek therapy, according to MindMed research.

Sales of anxiety and depression-related disease products and clinical trials are increasing in the global market because of the demand for appropriate management of these disorders as well as strong outreach activities. The United States will continue to be the largest user of anxiety disorder and depression treatment products throughout the analysis period accounting for over US$ 1.5 billion absolute dollar opportunity in the coming 10-year period.

How are key drivers going to affect the Anxiety Disorders and Depression Treatment Market?

Strong support for Research and Development (R&D) funding from the government and international healthcare organizations has spurred the revenue growth of the anxiety disorders and depression treatment market. Around 76 thousand grants for mental health were active between 2015 and 2020 from 345 funders in 38 nations. About 5% of all registered grants and 4% of the overall research spending, or US$ 18.5 billion, were related to mental health. With 89%, high-income nations received the majority of investments while the United States provided 39% of all grants. These investments are probably expected to help the market for treating anxiety disorders and depression in several ways.

Globally, patient care for mental health diseases is being enhanced through research and development. There are now more candidates for the treatment of anxiety disorders and depression in the pipeline owing to innovative research that has resulted in combination therapies using novel or existing medication molecules. For instance, the USA FDA recently approved LY03005, an antidepressant medicine manufactured by Luye Pharma.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the restraints to the growth of the Anxiety Disorders and Depression Treatment Market?

High drug dosages used to treat damaged neurological cells typically cause harm to healthy cells in the body. Many people experience a variety of negative effects as a result of these, including weight gain, impaired vision, nausea, dizziness, and others.

As a result, these side effects from anxiety and depression medications are having a detrimental impact on the demand for therapy, and the unavailability of resources available is another issue impeding market expansion. For instance, according to WHO research, between 44% and 70% of patients in industrialized countries do not obtain treatment, whereas in developing countries the difference is significantly greater and is close to 90%.

Region-wise Insights

In what ways does the Anxiety Disorders and Depression Treatment Market in North America have a bright future?

Due to the availability of numerous branded formulations impacting the market dynamics, North America accounts for the largest market share of anxiety disorders and depression treatment accounting for over 45%. As a result of the present pandemic, the demand for therapies for anxiety disorders and depression has increased. For instance, according to Bloomberg, the prescription rate for the anti-anxiety medication Zoloft increased by 12% in March 2020. Lockdowns, financial hardships, and a lack of physical contact have been cited as the main causes of a significant rise in depression and anxiety cases in North America.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

The USA Anxiety Disorders and Depression Treatment Market Analysis

The United States will account for US$ 5.6 billion of the global Anxiety Disorders and Depression Treatment Market by 2032. Anxiety Disorders and Depression Treatment Market growth in the USA from 2015 to 2021 was estimated at 2.3% CAGR. Researchers from Boston University found that half of the adults polled in the USA in September 2020 showed some symptoms of depression, such as feelings of helplessness and failure. These alarming statistics promise a further higher market for anxiety disorders and depression treatment market in the country.

The United Kingdom Anxiety Disorders and Depression Treatment Market Analysis

The anxiety Disorders and Depression market in the United Kingdom are expected to reach a valuation of US$ 665.5 million by 2032. The market in the country is projected to gross an absolute dollar opportunity of US$ 141.2 million from 2022 to 2032 and register a CAGR of 2.4%.

Japan Anxiety Disorders and Depression Treatment Market Analysis

The market in Japan is expected to garner an absolute dollar opportunity of US$ 151.8 million in 2022. The market in the country is expected to reach a valuation of US$ 932.2 million by 2032, growing at a CAGR of 1.8% from 2022 to 2032.

South Korea Anxiety Disorders and Depression Treatment Market Analysis

The market in South Korea is expected to expand at a CAGR of 1.4% from 2022 to 2032. The market is expected to swell at an absolute dollar opportunity of US$ 77.2 million from 2022 to 2032. By 2032, the market in the country is likely to reach a valuation of US$ 566.8 million.

Category-wise Insights

Why is depression taking center stage in the global Anxiety Disorders and Depression Treatment Market?

The market growth through the depression segment expanded at a CAGR of 2.4% from 2015 to 2021. According to WHO, depression affects an estimated 3.8% of the world's population, including 5% of adults and 5.7% of persons over the age of 60. Suicide can result from depression at its worst. Every year, suicide claims the lives of more than 700 thousand people. For people aged 15 to 29, suicide is the fourth most common cause of death. More than 75.0% of people in low- and middle-income countries do not obtain treatment for mental problems despite the fact that there are well-established, efficient treatments.

Competitive Landscape

Companies that offer treatment for anxiety disorders and depression frequently form joint ventures, buy sister companies, and work to obtain the FDA to approve their treatments. There has also been a significant investment in R&D for some cutting-edge products.

The key companies operating in the Anxiety Disorders and Depression Treatment Market include Pfizer Inc, H. Lundbeck A/S, Glaxo SmithKline pharmaceuticals ltd, Merck & Co., Inc, Eli Lilly & Company, AstraZeneca, H. Lundbeck A/S, Bristol-Myers Squibb, Johnson & Johnson, AbbVie Inc., Sanofi, Novartis AG, Forest Laboratories, Inc., Alembic pharma, Janssen Pharmaceutical N.V., and Cadent Therapeutics.

Some of the recent developments by key providers of the Anxiety Disorders and Depression Treatment Market are as follows:

  • In July 2021, Desipramine hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg were approved by the US FDA for the treatment of depression.
  • In May 2021, the PALISADE-a phase 3 trials, a randomized, double-blind, placebo-controlled research to assess the efficacy and safety of PH94B for the acute treatment of anxiety in people with a social anxiety disorder, was launched as part of VisataGen Therapeutics Inc.'s PALISADE Phase-3 clinical program (SAD).
  • In November 2020, in order to aid patients with treatment-resistant major depressive disorder, Janssen Pharmaceutical N.V. worked with the mental healthcare provider Koa Health to conduct research on how to give digital cognitive behavioral therapy alongside pharmacological treatment.
  • In August 2020, the USA Food And Drug Administration (FDA) approved an application to add intranasal SPRAVATO, a nasal spray, with an oral antidepressant to Treat depressive symptoms in adults with major depressive disorder and abrupt suicidal ideation or behavior. This was announced by Janssen Pharmaceuticals N.V.
  • In June 2020, an agreement was reached between Neurocrine Bioscience, Inc. and Takeda Pharmaceutical Company Limited to work together on developing new treatments for psychiatric diseases.
  • In December 2020, Novartis announced that it would acquire Cadent Therapeutics for up to US$ 770 million in total consideration. With the acquisition, Novartis will be able to take advantage of Cadent's full neuroscience portfolio and increase its market share in the field of mental health.
  • In December 2020, a merger deal was signed by Big Rock Partners Acquisition Corp. and NeuroRx, a company developing cutting-edge treatments for COVID-19 and bipolar illness.
  • In December 2020, the European Medicines Agency (EMA) accepted H. Lundbeck A/submission S's for Vyepti for assessment of the Marketing Authorization Application (MAA). The application asks for permission to make Vyepti available to European residents who suffer from migraine and are qualified for preventative therapy. The goal of Vyepti is to stop calcitonin gene-related peptide (CGRP) from interacting with its receptor, which will stop migraine attacks.

Similarly, recent developments related to companies providing services for Anxiety Disorders and Depression Treatment have been tracked by the team at Future Market Insights, which is available in the full report.

Key Segments Covered in Anxiety Disorders and Depression Treatment Market Survey

Anxiety Disorders and Depression Treatment Market by Drug Class:

  • Antidepressants
  • Anxiolytics
  • Anticonvulsants
  • Noradrenergic Agents
  • Atypical Antipsychotics

Anxiety Disorders and Depression Treatment Market by Indication:

  • Anxiety
  • Depression

Anxiety Disorders and Depression Treatment Market by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Anxiety Disorders and Depression Treatment Market by Region:

  • North America
  • Latin America
  • Europe Anxiety
  • Asia Pacific Anxiety
  • Middle East & Africa

Frequently Asked Questions

How much is the global Anxiety Disorders and Depression Treatment Market currently worth?

The global Anxiety Disorders and Depression Treatment Market was valued at US$ 11.2 billion in 2021.

What is the Anxiety Disorders and Depression Treatment Market Forecast through 2032?

The Anxiety Disorders and Depression Treatment Market is set to witness a growth rate of 3.4% over the forecast period and be valued at US$ 16.1 billion by 2032.

At what rate did demand for Anxiety Disorders and Depression Treatment Market increase over the past 6 years?

The Anxiety Disorders and Depression Treatment Market expanded by CAGR 2.7% from 2015 through 2021.

Who are the key players shaping the Anxiety Disorders and Depression Treatment Market?

The key players in the Anxiety Disorders and Depression Treatment Market are Pfizer Inc, H. Lundbeck A/S, Glaxo Smithkline Pharmaceuticals Ltd, Merc Co Inc, Eli Lilly & Company.

Who are the top 5 countries driving the highest sales in the Anxiety Disorders and Depression Treatment Market?

United States, United Kingdom, China, Japan, and South Korea are expected to drive the most sales growth in the Anxiety Disorders and Depression Treatment Market.

What is the China market outlook for Anxiety Disorders and Depression Treatment?

The Anxiety Disorders and Depression Treatment Market in China account for US$ 665.6 Mn of the global market share by end of the forecast year.

Which country has the largest market share of the Anxiety Disorders and Depression Treatment Market?

The United States held the largest market share of the Anxiety Disorders and Depression Treatment Market with US$ 1.5 billion of absolute dollar opportunity.

Table of Content

1. Executive Summary | Anxiety Disorders And Depression Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Investment Feasibility Matrix

    3.4. PESTLE and Porter’s Analysis

    3.5. Regulatory Landscape

        3.5.1. By Key Regions

        3.5.2. By Key Countries

4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032

    4.1. Historical Market Size Value (US$ million) Analysis, 2015 to 2021

    4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) Analysis By Drug Class, 2015 to 2021

    5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Class, 2022 to 2032

        5.3.1. Antidepressants

        5.3.2. Anxiolytics

        5.3.3. Anticonvulsants

        5.3.4. Noradrenergic Agents

        5.3.5. Atypical Antipsychotics

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2015 to 2021

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2022 to 2032

6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) Analysis By Indication, 2015 to 2021

    6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Indication, 2022 to 2032

        6.3.1. Anxiety

        6.3.2. Depression

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2015 to 2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032

7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2015 to 2021

    7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2022 to 2032

        7.3.1. Hospital Pharmacy

        7.3.2. Retail Pharmacy

        7.3.3. Online pharmacy

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2015 to 2021

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032

8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ million) Analysis By Region, 2015 to 2021

    8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. East Asia

        8.3.5. South Asia

        8.3.6. Oceania

        8.3.7. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Indication

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Indication

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Argentina

            10.2.1.4. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Indication

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Indication

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. Italy

            11.2.1.3. France

            11.2.1.4. The United Kingdom

            11.2.1.5. Spain

            11.2.1.6. Russia

            11.2.1.7. BENELUX

            11.2.1.8. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Indication

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Indication

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By Indication

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Indication

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Thailand

            13.2.1.3. Malaysia

            13.2.1.4. Indonesia

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Class

        13.2.3. By Indication

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Class

        14.2.3. By Indication

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country

    15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021

    15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032

        15.2.1. By Country

            15.2.1.1. GCC

            15.2.1.2. Rest of MEA

        15.2.2. By Drug Class

        15.2.3. By Indication

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Indication

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. The USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2021

            16.1.2.1. By Drug Class

            16.1.2.2. By Indication

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2021

            16.2.2.1. By Drug Class

            16.2.2.2. By Indication

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2021

            16.3.2.1. By Drug Class

            16.3.2.2. By Indication

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2021

            16.4.2.1. By Drug Class

            16.4.2.2. By Indication

            16.4.2.3. By Distribution Channel

    16.5. Argentina

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2021

            16.5.2.1. By Drug Class

            16.5.2.2. By Indication

            16.5.2.3. By Distribution Channel

    16.6. Germany

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2021

            16.6.2.1. By Drug Class

            16.6.2.2. By Indication

            16.6.2.3. By Distribution Channel

    16.7. Italy

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2021

            16.7.2.1. By Drug Class

            16.7.2.2. By Indication

            16.7.2.3. By Distribution Channel

    16.8. France

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2021

            16.8.2.1. By Drug Class

            16.8.2.2. By Indication

            16.8.2.3. By Distribution Channel

    16.9. The United Kingdom

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2021

            16.9.2.1. By Drug Class

            16.9.2.2. By Indication

            16.9.2.3. By Distribution Channel

    16.10. Spain

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2021

            16.10.2.1. By Drug Class

            16.10.2.2. By Indication

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2021

            16.11.2.1. By Drug Class

            16.11.2.2. By Indication

            16.11.2.3. By Distribution Channel

    16.12. BENELUX

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2021

            16.12.2.1. By Drug Class

            16.12.2.2. By Indication

            16.12.2.3. By Distribution Channel

    16.13. China

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2021

            16.13.2.1. By Drug Class

            16.13.2.2. By Indication

            16.13.2.3. By Distribution Channel

    16.14. Japan

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2021

            16.14.2.1. By Drug Class

            16.14.2.2. By Indication

            16.14.2.3. By Distribution Channel

    16.15. South Korea

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2021

            16.15.2.1. By Drug Class

            16.15.2.2. By Indication

            16.15.2.3. By Distribution Channel

    16.16. India

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2021

            16.16.2.1. By Drug Class

            16.16.2.2. By Indication

            16.16.2.3. By Distribution Channel

    16.17. Thailand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2021

            16.17.2.1. By Drug Class

            16.17.2.2. By Indication

            16.17.2.3. By Distribution Channel

    16.18. Malaysia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2021

            16.18.2.1. By Drug Class

            16.18.2.2. By Indication

            16.18.2.3. By Distribution Channel

    16.19. Indonesia

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2021

            16.19.2.1. By Drug Class

            16.19.2.2. By Indication

            16.19.2.3. By Distribution Channel

    16.20. Australia

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2021

            16.20.2.1. By Drug Class

            16.20.2.2. By Indication

            16.20.2.3. By Distribution Channel

    16.21. New Zealand

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2021

            16.21.2.1. By Drug Class

            16.21.2.2. By Indication

            16.21.2.3. By Distribution Channel

    16.22. GCC Countries

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2021

            16.22.2.1. By Drug Class

            16.22.2.2. By Indication

            16.22.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Indication

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Pfizer Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. H. Lundbeck A/S

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Glaxo smithkline pharmaceuticals ltd.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. Merc Co Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. Merc Co Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. Eli Lilly & Company

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. AstraZeneca

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. H. Lundbeck A/S

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

        18.1.9. Bristol-Myers Squibb

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

                18.1.9.5.2. Product Strategy

                18.1.9.5.3. Channel Strategy

        18.1.10. Johnson & Johnson

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

                18.1.10.5.2. Product Strategy

                18.1.10.5.3. Channel Strategy

        18.1.11. AbbVie Inc.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

                18.1.11.5.2. Product Strategy

                18.1.11.5.3. Channel Strategy

        18.1.12. Sanofi

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

                18.1.12.5.2. Product Strategy

                18.1.12.5.3. Channel Strategy

        18.1.13. Novartis AG

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

                18.1.13.5.2. Product Strategy

                18.1.13.5.3. Channel Strategy

        18.1.14. Forest Laboratories, Inc.

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

                18.1.14.5.2. Product Strategy

                18.1.14.5.3. Channel Strategy

        18.1.15. Alembic Pharma

            18.1.15.1. Overview

            18.1.15.2. Product Portfolio

            18.1.15.3. Profitability by Market Segments

            18.1.15.4. Sales Footprint

            18.1.15.5. Strategy Overview

                18.1.15.5.1. Marketing Strategy

                18.1.15.5.2. Product Strategy

                18.1.15.5.3. Channel Strategy

        18.1.16. Janssen Pharmaceutical N.V.

            18.1.16.1. Overview

            18.1.16.2. Product Portfolio

            18.1.16.3. Profitability by Market Segments

            18.1.16.4. Sales Footprint

            18.1.16.5. Strategy Overview

                18.1.16.5.1. Marketing Strategy

                18.1.16.5.2. Product Strategy

                18.1.16.5.3. Channel Strategy

        18.1.17. Cadent Therapeutics

            18.1.17.1. Overview

            18.1.17.2. Product Portfolio

            18.1.17.3. Profitability by Market Segments

            18.1.17.4. Sales Footprint

            18.1.17.5. Strategy Overview

                18.1.17.5.1. Marketing Strategy

                18.1.17.5.2. Product Strategy

                18.1.17.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ million) Forecast by Region, 2015 to 2032

Table 2: Global Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 3: Global Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 4: Global Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 5: North America Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 6: North America Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 7: North America Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 8: North America Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 9: Latin America Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 10: Latin America Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 11: Latin America Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 12: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 13: Europe Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 14: Europe Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 15: Europe Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 16: Europe Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 17: East Asia Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 18: East Asia Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 19: East Asia Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 20: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 21: South Asia Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 22: South Asia Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 23: South Asia Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 24: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 25: Oceania Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 26: Oceania Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 27: Oceania Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 28: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032

Table 29: MEA Market Value (US$ million) Forecast by Country, 2015 to 2032

Table 30: MEA Market Value (US$ million) Forecast by Drug Class, 2015 to 2032

Table 31: MEA Market Value (US$ million) Forecast by Indication, 2015 to 2032

Table 32: MEA Market Value (US$ million) Forecast by Distribution Channel, 2015 to 2032
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 2: Global Market Value (US$ million) by Indication, 2022 to 2032

Figure 3: Global Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 4: Global Market Value (US$ million) by Region, 2022 to 2032

Figure 5: Global Market Value (US$ million) Analysis by Region, 2015 to 2032

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032

Figure 8: Global Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 11: Global Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 14: Global Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 17: Global Market Attractiveness by Drug Class, 2022 to 2032

Figure 18: Global Market Attractiveness by Indication, 2022 to 2032

Figure 19: Global Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 20: Global Market Attractiveness by Region, 2022 to 2032

Figure 21: North America Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 22: North America Market Value (US$ million) by Indication, 2022 to 2032

Figure 23: North America Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 24: North America Market Value (US$ million) by Country, 2022 to 2032

Figure 25: North America Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 28: North America Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 31: North America Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 34: North America Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 37: North America Market Attractiveness by Drug Class, 2022 to 2032

Figure 38: North America Market Attractiveness by Indication, 2022 to 2032

Figure 39: North America Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 40: North America Market Attractiveness by Country, 2022 to 2032

Figure 41: Latin America Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 42: Latin America Market Value (US$ million) by Indication, 2022 to 2032

Figure 43: Latin America Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 44: Latin America Market Value (US$ million) by Country, 2022 to 2032

Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 48: Latin America Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 51: Latin America Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 54: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 57: Latin America Market Attractiveness by Drug Class, 2022 to 2032

Figure 58: Latin America Market Attractiveness by Indication, 2022 to 2032

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032

Figure 61: Europe Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 62: Europe Market Value (US$ million) by Indication, 2022 to 2032

Figure 63: Europe Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 64: Europe Market Value (US$ million) by Country, 2022 to 2032

Figure 65: Europe Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 68: Europe Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 71: Europe Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 72: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 74: Europe Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 77: Europe Market Attractiveness by Drug Class, 2022 to 2032

Figure 78: Europe Market Attractiveness by Indication, 2022 to 2032

Figure 79: Europe Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 80: Europe Market Attractiveness by Country, 2022 to 2032

Figure 81: East Asia Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 82: East Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 83: East Asia Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 84: East Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 85: East Asia Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 88: East Asia Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 89: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 91: East Asia Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 92: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 94: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 97: East Asia Market Attractiveness by Drug Class, 2022 to 2032

Figure 98: East Asia Market Attractiveness by Indication, 2022 to 2032

Figure 99: East Asia Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032

Figure 101: South Asia Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 102: South Asia Market Value (US$ million) by Indication, 2022 to 2032

Figure 103: South Asia Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 104: South Asia Market Value (US$ million) by Country, 2022 to 2032

Figure 105: South Asia Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 108: South Asia Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 109: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 111: South Asia Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 112: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 114: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 115: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 117: South Asia Market Attractiveness by Drug Class, 2022 to 2032

Figure 118: South Asia Market Attractiveness by Indication, 2022 to 2032

Figure 119: South Asia Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 120: South Asia Market Attractiveness by Country, 2022 to 2032

Figure 121: Oceania Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 122: Oceania Market Value (US$ million) by Indication, 2022 to 2032

Figure 123: Oceania Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 124: Oceania Market Value (US$ million) by Country, 2022 to 2032

Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 128: Oceania Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 131: Oceania Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 134: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 137: Oceania Market Attractiveness by Drug Class, 2022 to 2032

Figure 138: Oceania Market Attractiveness by Indication, 2022 to 2032

Figure 139: Oceania Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 140: Oceania Market Attractiveness by Country, 2022 to 2032

Figure 141: MEA Market Value (US$ million) by Drug Class, 2022 to 2032

Figure 142: MEA Market Value (US$ million) by Indication, 2022 to 2032

Figure 143: MEA Market Value (US$ million) by Distribution Channel, 2022 to 2032

Figure 144: MEA Market Value (US$ million) by Country, 2022 to 2032

Figure 145: MEA Market Value (US$ million) Analysis by Country, 2015 to 2032

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032

Figure 148: MEA Market Value (US$ million) Analysis by Drug Class, 2015 to 2032

Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032

Figure 151: MEA Market Value (US$ million) Analysis by Indication, 2015 to 2032

Figure 152: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032

Figure 154: MEA Market Value (US$ million) Analysis by Distribution Channel, 2015 to 2032

Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032

Figure 157: MEA Market Attractiveness by Drug Class, 2022 to 2032

Figure 158: MEA Market Attractiveness by Indication, 2022 to 2032

Figure 159: MEA Market Attractiveness by Distribution Channel, 2022 to 2032

Figure 160: MEA Market Attractiveness by Country, 2022 to 2032

Recommendations

Healthcare

Frontotemporal Disorders Treatment Market

Published : July 2022

Healthcare

Amino Acid Metabolism Disorders Treatment Market

Published : February 2018

Explore Healthcare Insights

View Reports

Anxiety Disorders And Depression Treatment Market